The US Food and Drug Administration (FDA) has issued draft guidance for a new regulatory framework for drug sponsors seeking approval for targeted individualized therapies for ultra-rare diseases.
The so-called plausible mechanism framework aims to reduce hurdles for individualized medicines designed for patients with diseases so uncommon that it may